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Abstract 
Background: Staphylococcus aureus (S. aureus) has established itself over the years as a major cause of morbidity and 
mortality both within the community and in healthcare settings. Methicillin resistant S. aureus (MRSA) in particular has 
been a major cause of nosocomial infections resulting in significant increase in healthcare costs. In Africa, the MRSA 
prevalence has been shown to vary across different countries. In order to better understand the epidemiology of 
MRSA in a setting, it is important to define its population structure using molecular tools as different clones have been 
found to predominate in certain geographical locations.
Methods: We carried out PFGE, MLST, SCCmec and spa typing of selected S. aureus isolates from a private and public 
referral hospital in Nairobi, Kenya.
Results: A total of 93 S. aureus isolates were grouped into 19 PFGE clonal complexes (A–S) and 12 singletons. From 
these, 55 (32 MRSA and 23 MSSA) representative isolates from each PFGE clonal complex and all singletons were spa 
typed. There were 18 different MRSA spa types and 22 MSSA spa types. The predominant MRSA spa type was t037 
comprising 40.6 % (13/32) of all MRSA. In contrast, the MSSA were quite heterogeneous, only 2 out of 23 MSSA shared 
the same spa type. Two new MRSA spa types (t13149 and t13150) and 3 new MSSA spa types (t13182, t13193 and 
t13194) were identified. The predominant clonal complex was CC 5 which included multi-locus sequence types 1, 8 
and 241.
Conclusion: In contrast to previous studies published from Kenya, there’s marked genetic diversity amongst clinical 
MRSA isolates in Nairobi including the presence of well-known epidemic MRSA clones. Given that these clones are 
resident within our referral hospitals, adherence to strict infection control measures needs to be ensured to reduce 
morbidity and mortality associated with hospital acquired MRSA infections.
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Background
Staphylococcus aureus (S. aureus) has established itself 
over the years as a major cause of morbidity and mortal-
ity globally both within the community and in healthcare 
settings [1–3]. Its ability to cause disease is aided not only 
by its impressive repertoire of virulence factors but also 
its ability to develop resistance to antibiotics used in its 
treatment epitomized by the emergence of methicillin 
resistant S. aureus (MRSA). Methicillin resistance is con-
ferred by the mecA gene that is carried on a staphylococ-
cal cassette chromosome mec (SCCmec) and codes for a 
modified penicillin binding protein (PBP2a). This bind-
ing protein has reduced affinity to all beta-lactam and 
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beta-lactam/beta-lactamase inhibitor combination anti-
biotics [4, 5]. In Africa, the MRSA prevalence has been 
shown to vary across different countries with a preva-
lence as low as 7 % reported in Madagascar and as high 
as 82 % in Egypt [6]. This marked variation could be due 
to different environmental determinants or simply due to 
a difference in the genetic diversity of S. aureus. In Kenya, 
there is a marked difference in reported MRSA preva-
lence in clinical isolates within Nairobi with one recent 
study reporting a prevalence of 3.7  % while another 
reported 87.2  % [7, 8]. In order to better understand 
the epidemiology of MRSA, it is important to define its 
population structure. Molecular characterization helps in 
identifying clonal populations which can help in surveil-
lance and investigation of outbreaks.
There is a growing interest in the characterization of 
MRSA isolates and this stems primarily from its role 
as a major cause of hospital and community acquired 
infections [1, 9, 10]. There are various molecular meth-
ods used, the more common ones include multi-locus 
sequence typing (MLST), pulse field gel electrophoresis 
(PFGE), staphylococcal protein A (spa) typing and SCC-
mec typing [11].  Despite S. aureus having a very diverse 
clonal population, MLST studies have shown that a small 
set of clonal complexes (CC) are associated with most of 
the MRSA epidemics. These include CC5, CC22, CC30, 
CC45 and CC80 [6, 12, 13]. A clonal complex can have 
several sequence types, however the multi-locus sequence 
types that are regarded as the founders in these clonal 
complexes are ST5, ST22, ST30, ST45 and ST80 respec-
tively [14]. As regards spa types, it has been shown that 
particular ones are more predominant in certain regions. 
For example t030 is quite predominant in hospitals in 
Turkey [15], t042 and t044 are more common in North 
Africa while t008 is common in the US [16]. Unfortu-
nately, the molecular epidemiology of MRSA in Africa is 
not very well described. Most of the studies carried out 
in Africa characterizing MRSA have emanated from a few 
countries namely Tunisia, Nigeria, South Africa, Algeria 
and Egypt [6]. There are very few studies from East Africa 
that have reported on the molecular characterization of S. 
aureus presumably due to lack of readily available tech-
nical expertise and laboratory facilities. A study done in 
Kenya looking at carriage of S. aureus by inpatients in a 
government hospital found that only 6 out of 86 (7 %) S. 
aureus isolates were MRSA and they all belonged to the 
same clone (MLST ST239; spa type t037) [17]. This clone 
is a globally distributed hybrid of ST8 and ST30 and is 
known to be responsible for several outbreaks in different 
continents [18–21]. The only other study from Kenya did 
not report on spa or multi locus sequence types [8].
We set out to characterize selected S. aureus isolates 
from different hospitals in Nairobi, Kenya in order to 
identify which clonal lineages are present and further 
shed light on the molecular epidemiology of both MSSA 
and MRSA in Kenya.
Methods
We obtained archived methicillin susceptible (MSSA) 
and MRSA isolates from 2 hospitals in Nairobi, Kenya 
collected between January 2010 and July 2013. The hos-
pitals included a government hospital whose samples we 
obtained through the Kenya Medical Research Institute 
(KEMRI) and the Aga Khan University Hospital Nairobi 
(AKUHN) which is a private referral hospital with a net-
work of satellite clinics and laboratories spread in and 
around Nairobi as well as different parts of the country. 
The isolates from the government hospital were part of 
a previous study done to determine prevalence of MRSA 
carriage in a paediatric ward and the rest of the isolates 
were from clinical specimens submitted to the AKUHN 
laboratory for routine culture and sensitivity. These were 
convenience isolates that were not collected through a 
well-structured, formal and documented process. All 
isolates were stored at −80  °C and grown overnight on 
sheep blood agar plates at 37 °C.
S. aureus identification
All isolates were confirmed to be S. aureus using routine 
bench identification methods which included growth 
characteristics on sheep blood agar, gram stain, catalase, 
coagulase, deoxyribonuclease (DNase) and mannitol 
fermentation tests. A cefoxitin screen using a 30 µg disc 
(Oxoid, United Kingdom) was performed to distinguish 
MSSA from MRSA. Isolates with a diameter  ≤21  mm 
were classified as MRSA.
Antibiotic susceptibility
Antibiotic susceptibility was only available for the MRSA 
isolates obtained from AKUHN. These were performed 
on Vitek 2 (version 4.01, bioMerieux, Marcy-l’Etoile, 
France) an automated bacterial identification system that 
performs antibiotic susceptibility using broth dilution 
and interpretation based on Clinical Laboratory Stand-
ards Institute (CLSI) antimicrobial susceptibility guide-
lines [22]. Multidrug resistance (MDR) was defined as 
resistance to three or more drug classes.
DNA derivation
Isolates were grown on blood agar plates (National 
Health Laboratory Services Media Lab, Cape Town, 
South Africa) at 37  °C overnight. After incubation, 4–5 
large colonies were re-suspended in 200 µL nuclease free 
water. The samples were incubated at 95  °C for 30 min, 
followed by −80 °C for 30 min and centrifuged for 10 min 
at 14,000×g when thawed. The supernatant containing 
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DNA was carefully aspirated without disturbing the pel-
let of cell debris and stored as DNA aliquots at −20° C 
until further use.
PFGE
PFGE based on SmaI macrorestriction analysis was 
performed using the CDC laboratory protocol for S. 
aureus [23]. The PFGE was run on a CHEF DR III sys-
tem (Bio-Rad, California, United States of America) with 
optimum settings as follows: initial 5 s, switch 30 s, run 
time 29  h, voltage 6 V/cm and a SeaKem Gold agarose 
(Lonza, Rockland, USA) gel concentration of 1.4  %. S. 
aureus NCTC 8325 was used as a control in each gel run. 
Gels were visualized an Alliance 2.7 (UVItec, Cambridge, 
United Kingdom) gel documentation system after stain-
ing with 10 mg/mL ethidium bromide. Analysis of PFGE 
clusters was performed using the BioNumerics software 
package (Applied Maths, Sint-Martens-Latem, Belgium), 
using the Dice coefficient, and visualized as a dendro-
gram by the unweighted-pair group method, using aver-
age linkages with 1  % tolerance and 1  % optimization 
settings. In order to define a cluster, a cutoff of 80 % simi-
larity was used.
SCCmec typing
SCCmec typing was performed using multiplex PCR as 
described by Milheirico et  al. [24]. All assays were per-
formed in a GeneAmp 9600 thermocycler (Applied 
Biosystems). The optimal cycling conditions were the 
following: 95  °C for 5  min; 35 cycles of 95  °C for 45  s, 
57 °C for 45 s, and 72 °C for 1 min; and a final extension 
at 72 °C for 10 min. Each PCR mixture contained 0.5 µL 
of the primers listed in Table  1, KAPA2G Robust Hot-
Start ReadyMix PCR (KAPA biosystems) which contains 
KAPA2G Robust HotStart DNA Polymerase (1 U/25 
µL reaction) in a proprietary reaction buffer containing 
dNTPs (0.2 mM of each dNTP at 1X), MgCl2 (2 mM at 
1X), 0.3  µL (3  mM) additional MgCl2, 10.7  µL of PCR 
grade water and genomic DNA in a final volume of 25 µL. 
The following S. aureus isolates were used as controls: 
BAA-38, BAA-1681, BAA-39, BAA-1680, BAA-1688 and 
BAA-42 for SCCmec types I–VI respectively. The PCR 
products were resolved in a 1  % SeaKem Gold Agarose 
(Lonza, Rockland, USA) gel in 0.5  % Tris–borate-ethyl-
ene-diamine-tetra-acetic acid (EDTA) buffer (Bio-Rad, 
Hercules, CA) at 4  V/cm for 2.5  h and were visualized 
with ethidium bromide.
spa typing
This was done using the following primers: 1095 F: 
5′-AGACGATCCTTCGGTGAGC-3′ and 1517R: 
5′-GCTTTTGCAATGTCATTTACTG-3′. PCR reac-
tions consisted of 12.5  uL of KAPA2G Robust HotStart 
ReadyMix PCR (KAPA biosystems) which contains 
KAPA2G Robust HotStart DNA Polymerase (1 U per 
25 µL reaction) in a proprietary reaction buffer con-
taining dNTPs (0.2  mM of each dNTP at 1X), MgCl2 
(2 mM at 1X), 0.5 μM of primers and genomic DNA in 
a final volume of 25 µL. PCR conditions were 95  °C for 
6 min; 30 cycles each of 95 °C for 45 s, 64 °C for 45 s, and 
72  °C for 60  s; and a final extension at 72  °C for 6 min. 
Sequencing was outsourced to inqaba biotec, a biotech-
nology company based in Pretoria, South Africa. Using 
the Ridom spa server (http://www.spa.server.ridom.de), 
spa sequences were automatically assigned to spa types. 
Sequence types and clonal complexes (spa-CC) were 
assigned where possible using Based Upon Repeat Pat-
terns (BURP) grouping analysis from the Ridom Staph-
Type software (version 1.4; Ridom GmbH, Würzburg, 
Germany). For BURP analysis, default parameters were 
used which allows spa types with maximum 4 genetic dif-
ferences to be grouped into one cluster resulting in a cal-
culated cost between members of a group being less than 
or equal to 4.
MLST
MLST was done on representative isolates from each 
PFGE clonal complex and selected singletons according 
to the protocol published by Enright et al. [25]. The PCRs 
were carried out as uniplex reactions consisting of 1 µM 
of the forward and reverse primers, 12.5 µL of 2× KAPA 
Taq ReadyMix (KAPA Biosystems), 2.5 mM MgCl2, 1 µL 
of template DNA and nuclease free water up to 25 µL. 
The PCR conditions were 95  °C for 5  min, followed by 
30 cycles of 95  °C for 45 s, 56  °C for 45 s and 72  °C for 
1  min. A final elongation step was carried out at 72  °C 
for 10 min. 5 µL of the PCR product was visualised with 
gel electrophoresis at 120 V for 1 h. Sequencing was per-
formed on the remainder of the PCR product by Inqaba 
Biotechnical Industries (Pty) Ltd (Pretoria, South Africa). 
Sequences were inspected and trimmed in BioEdit 
Sequence Alignment Editor using reference sequences 
for each of the seven loci. A consensus sequence was 
generated from the forward and reverse sequences and 
used to generate sequence types (STs) on the S. aureus 
MLST database (http://www.saureus.beta.mlst.net/#). 
Isolates that were not typed by MLST were assigned STs 
using BURP analysis. Isolates with the same PFGE clonal 
complex and spa type were assigned the same STs. MLST 
clonal complexes (MLST-CC) were determined using a 
Java applet found at http://www.eburst.mlst.net that uses 
the eBURST algorithm. The default setting was used in 
which STs that share identical alleles at 6 or 7 of MLST 
loci are put in the same group. Where there was a dis-
crepancy between the CC determined using eBURST and 
BURP, we considered the MLST-CC as the correct one.
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Results
A total of 93 S. aureus isolates underwent PFGE. These 
were subsequently grouped into 19 PFGE clonal com-
plexes (A–S) and 12 singletons. From these, 55 (32 
MRSA and 23 MSSA) representative isolates from each 
PFGE clonal complex and all singletons were spa typed. 
This comprised 41 isolates from AKUHN and 14 from 
KEMRI. In total, there were 18 different MRSA spa types 
and 22 different spa types amongst the MSSA. The pre-
dominant MRSA spa type was t037 comprising 40.6  % 
(13/32) of all MRSA. In contrast, the MSSA were quite 
heterogeneous, only 2 out of 23 MSSA shared the same 
spa type. Two new MRSA spa types (t13149 and t13150) 
and 3 new MSSA spa types (t13182, t13193, t13194) were 
identified as shown in Table 2. Three spa types (t005, t318 
and t1476) were found in both MSSA and MRSA. BURP 
analysis for both MSSA and MRSA revealed 7 spa-clonal 
complexes and 14 singletons as shown in Fig. 1. The pre-
dominant spa-CC was spa-CC005 which included the 
new MRSA spa type 13149. SCCmec type-III [3A] was 
the predominant type followed by SCCmec-IV [2B]. Only 
one MRSA isolate was non-typeable using the SCCmec 
protocol published by Milheirico et al. [24] 
MLST STs were determined and extrapolated for 31 
isolates. A total of seven different MRSA and MSSA 
MLST-CC were identified with the predominant one 
being MLST-CC 5. This clonal complex comprised STs 1, 
5, 8 and 241 as shown in Table  2. An isolate belonging 
to ST241 (t2029) that was detected in a pus sample from 
AKUHN hospital was found to harbor SCCmec type IV 
[2B].
Out of the 16 MRSA from AKUHN, 13 were MDR 
including the two new spa types. Resistance was com-
monly seen to clindamycin, erythromycin and tri-
methoprim/sulfamethoxazole (TMP/SMX). A number 
of isolates had intermediate resistance to levofloxacin. 
However, two isolates were only resistant to beta lactams 
but susceptible to all other antibiotics including TMP/
SMX as shown in Table 3. None of the MRSA was resist-
ant to vancomycin, linezolid, mupirocin, teicoplanin or 
tigecycline.
Discussion
This study reveals a markedly heterogeneous popula-
tion of S. aureus isolates as well as the presence of well 
described MRSA clonal complexes 5, 22 and 30 that are 
responsible for several outbreaks worldwide [13, 26]. 
CC5 has been identified as the major clonal complex 
causing HA-MRSA in Africa with MRSA ST239/ST241-
III [3A] having been identified in several African coun-
tries [6]. The main clonal complex in our study was CC5 
that included ST 241, a single locus variant of ST 239 also 
known as the “Brazilian/Hungarian clone”. ST 239 and ST 
239 like isolates are well-known epidemic clones respon-
sible for several healthcare associated MRSA outbreaks 
globally. They have been found to be a cause of hospital 
Table 1 Primers used in the updated version of SCCmec multiplex PCR
Primer name Primer sequence (5 33) Primer specificity (SCCmec type, region) Amplicon size (bp) Conc. (µM)
CIF2 F2 TTCGAGTTGCTGATGAAGAAGG I, J1 region 495 0.4
CIF2 R2 ATTTACCACAAGGACTACCAGC 0.4
ccrC F2 GTACTCGTTACAATGTTTGG V, ccr complex 449 0.8
ccrC R2 ATAATGGCTTCATGCTTACC 0.8
RIF5 F10 TTCTTAAGTACACGCTGAATCG III, J3 region 414 0.4
RIF5 R13 ATGGAGATGAATTACAAGGG 0.4
SCCmec V J1 F TTCTCCATTCTTGTTCATCC V, J1 region 377 0.4
SCCmec V J1 R AGAGACTACTGACTTAAGTGG 0.4
dcs F2 CATCCTATGATAGCTTGGTC I, II, IV, and VI, J3 region 342 0.8
dcs R1 CTAAATCATAGCCATGACCG 0.8
ccrB2 F2 AGTTTCTCAGAATTCGAACG II and IV, ccr complex 311 0.8
ccrB2 R2 CCGATATAGAAWGGGTTAGC 0.8
kdp F1 AATCATCTGCCATTGGTGATGC II, J1 region 284 0.2
kdp R1 CGAATGAAGTGAAAGAAAGTGG 0.2
SCCmec III J1 F CATTTGTGAAACACAGTACG III, J1 region 243 0.4
SCCmec III J1 R GTTATTGAGACTCCTAAAGC 0.4
mecI P2 ATCAAGACTTGCATTCAGGC II and III, mec complex 209 0.8
mecI P3 GCGGTTTCAATTCACTTGTC 0.8
mecA P4 TCCAGATTACAACTTCACCAGG Internal positive control 162 0.8
mecA P7 CCACTTCATATCTTGTAACG 0.8
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Table 2 Molecular characterization of methicillin susceptible and resistant Staphylococcus aureus
Isolate No. Hospital Sample ID spa type spa-CC SCCmec type MLST/spa ST MLST CC PFGE CC PFGE pulsotype
36 AKUHN Pus swab MSSA t645 sng 1841a 121 A A2
84 AKUHN Pus swab MSSA t314 sng 121a 121 B B2
78 AKUHN Pus swab MSSA t355 sng 152a 152 C C1
48 AKUHN Pus swab MSSA t355 sng 152b 152 C C4
91 AKUHN Nasal swab MRSA t005 5 IV 22a 22 D D2
28 AKUHN Nasal swab MRSA t005 5 IV 22b 22 D D3
83 AKUHN Sputum MRSA t005 5 IV 22b 22 D D3
89 AKUHN Pus swab MRSA t13149d 5 IV NDc D D1
22 KEMRI Nasal swab MRSA t022 5 IV 22a 22 E E2
75 AKUHN Blood MRSA t9622 sng IV NDc E E1
15 AKUHN Pus swab MSSA t005 5 22a 22 F F6
12 AKUHN Pus swab MSSA t223 5 22a 22 G G2
71 AKUHN Pus swab MSSA t122 sng 30a 30 H H1
88 AKUHN Tracheal aspirate MSSA t318 sng 30a 30 I I5
16 AKUHN Pus swab MSSA t021 21 30a 30 I I7
23 AKUHN Sputum MRSA t1339 3202/186 UT 88a 88 J J2
49 KEMRI Nasal swab MRSA t3202 3202/186 UT NDc J J1
19 AKUHN Axillary swab MSSA t3841 sng 672a 672 K K2
6 AKUHN Nasal swab MRSA t091 NF3 V 789a 7 L L2
69 AKUHN Pus swab MSSA t2505 NF3 789a 7 L L1
14 AKUHN Tracheal aspirate MSSA t002 sng 5a 5 M M3
79 AKUHN Pus swab MRSA t13150d sng II 5a 5 M M2
52 AKUHN Blood MSSA t2473 sng 72a 72 N N3
92 AKUHN Blood MSSA t13193d 5 22a 22 O O1
87 AKUHN Blood MSSA t127 sng 1a 5 P P3
81 AKUHN Ear swab MRSA t1476 NF2 V 8a 5 Q Q1
45 AKUHN Pus swab MSSA t1476 NF2 8a 5 Q Q2
31 AKUHN Pus swab MSSA t064 sng 8a 5 R R4
33 KEMRI Nasal swab MRSA t104 NF1 IV 8a 5 R R2
7 KEMRI Nasal swab MRSA t689 NF1 I NDc R R1
25 AKUHN Blood MRSA t852 5 IV NDc R R5
4 AKUHN Sputum MRSA t037 NF4 III 241a 5 S S1
2 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S10
3 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S10
1 AKUHN Blood MRSA t037 NF4 III 241b 5 S S11
47 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S2
38 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S3
34 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S4
20 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S5
18 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S6
37 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S7
27 KEMRI Nasal swab MRSA t037 NF4 III 241b 5 S S9
29 AKUHN Pus swab MRSA t2029 NF4 IV 241a 5 S S8
13 AKUHN Pus swab MRSA t037 NF4 III 239/240/241c Sng12
11 AKUHN Pus swab MRSA t037 NF4 III 239/240/241c Sng6
17 AKUHN Pus swab MSSA t13182d sng NDc Sng 3
44 AKUHN Urine MSSA t13194d sng NDc Sng7
73 AKUHN Pus swab MSSA t1839 345 NDc Sng5
58 AKUHN Blood MSSA t186 3202/186 88c Sng4
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acquired infections in other African countries includ-
ing Algeria, Ghana, Morocco, South Africa and Nigeria 
[6]. A study done by Aiken et al. [17] in a public hospi-
tal that is approximately 40  km from Nairobi identified 
t037-ST239 as the predominant clone carried by inpa-
tients in a surgical ward. Most of the nasal swabs in our 
study were obtained from children in a paediatric ward 
situated in a public referral hospital. The high proportion 
of t037-ST241 among our MRSA isolates is not neces-
sarily reflective of the true prevalence of this spa type in 
Nairobi due to a selection bias in the manner in which 
the isolates were collected. Nevertheless, it is quite con-
cerning that a clone known to be associated with MRSA 
epidemics is resident within hospitals in Nairobi indicat-
ing an urgent need for proper infection control interven-
tions and regular surveillance.
sng singleton, NF no founder, UT untypeable, ND not defined on the Ridom database Accessed on 07/10/2015
a MLST ST
b MLST ST extrapolated based on similar spa type and pulsotype
c spa ST
d New spa type
Table 2 continued
Isolate No. Hospital Sample ID spa type spa-CC SCCmec type MLST/spa ST MLST CC PFGE CC PFGE pulsotype
70 AKUHN Blood MSSA t224 345 97c Sng8
21 AKUHN Pus swab MRSA t293 sng IV NDc Sng 2
43 KEMRI NASAL SWAB MRSA t318 sng IV 30c Sng 1
35 AKUHN Pus swab MRSA t345 345 V NDc Sng10
40 AKUHN Urine MRSA t648 NF2 IV NDc Sng11
85 AKUHN Vulval swab MSSA t131 345 NDc Sng9
Fig. 1 Based upon repeat pattern clustering analysis for all identified S. aureus isolates: the clustering analysis resulted in seven spa-clonal com-
plexes and 14 singletons. The blue circle represents the group founder and the circle size is proportional to the frequency of the spa type
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Unlike the study by Aiken et al. [17] that only found one 
MRSA clone, we identified 18 distinct spa types amongst 
the MRSA isolates belonging to very diverse sequence 
types, including 2 MRSA spa types (t13149 and t13150) 
that have not previously been described. The spa type 
t13150 was found to belong to ST5-II [2A] which has also 
been found in Nigeria and Senegal [27, 28]. We identified 
MRSA belonging to ST22 which in Africa has only pre-
viously been found in Algeria, Tunisia and South Africa. 
This clone has been widely associated with hospital epi-
demics especially in new born units [29]. The “West 
Australia MRSA-2 clone” (WA-MRSA-2), ST88-IV [2B] 
which has been reported in Cameroon and Madagascar 
was not found and the European MRSA clone ST80-IV 
that has been found in North African countries was not 
present in our collection. None of the MRSA in this study 
belonged to spa type t008, the prevalent spa type associ-
ated with the USA300 pulsotype that has been identified 
as the major cause of community acquired skin and soft 
tissue infections in North America [30, 31]. Although 
the isolates included in our study were few, they repre-
sent a fairly diverse collection from both a public and pri-
vate referral hospital and we can therefore conclude that 
USA300 is not common in Nairobi.
The 23 MSSA belonged to 22 different spa types high-
lighting their marked genetic diversity in contrast to the 
MRSA. There were 3 spa types (t005, t318 and t1476) that 
were found in both MSSA and MRSA suggesting the pos-
sibility of local acquisition of an SCCmec element. One 
of the MSSA spa types belongs to t002 which is associ-
ated with the MRSA pulsotype USA100 [16]. The spa 
type t064 was also found which is associated with one of 
the major MRSA clones (ST612- SCCmec IV [2B] found 
in South Africa [32]. ST241 has frequently been associ-
ated with SCCmec III [3A], however, one isolate belong-
ing to ST241 harbored SCCmec IV [2B] (this SCCmec 
element was more common in AKUHN hospital). This 
particular clone was previously observed in a large uni-
versity clinic in Nigeria [33]. SCCmec types IV and V are 
small in size and can be transmitted both in the commu-
nity and healthcare settings. Potentially, this could result 
in the emergence of well-known epidemic MRSA clones 
like the predominant European CA-MRSA clone ST80-
IV [2B] whose for bearer is thought to be a PVL-positive 
MSSA from sub-Saharan Africa that acquired the SCC-
mec IV [2B] [34]. The MSSA strain t021-ST30 has also 
been associated with a known PVL positive CA-MRSA 
clone [35].
The multi-drug resistant patterns for the MRSA in 
this study are in keeping with what has been described 
in other countries in Africa [17, 32, 36, 37]. Most of 
the MRSA were resistant to macrolide–lincosamide, 
Table 3 Molecular characterization and antibiotic susceptibility of MRSA isolates from AKUHN
R resistant, S susceptible, I intermediate, ERY erythromycin, CLI clindamycin, CLI# inducible clindamycin resistance, TET tetracycline, SXT trimethoprim/
sulfamethoxazole, VAN vancomycin, GENT gentamicin, MUP mupirocin, MOX moxifloxacin, RIF rifampicin, TIG tigecycline, TOB tobramycin, TEI teicoplanin, LNZ 
linezolid, LEV levofloxacin
a New spa type
Isolate No. Sample spa type SCCmec 
type
Antibiogram
R S I
21 Pus swab t293 IV [2B] TOB, CLI, ERY, LEV LNZ, TEI, VAN, TET, TIG, MUP, RIF, SXT, MOX
23 Sputum t1339 UT SXT TOB, MOX, ERY, CLI, VAN, TET, TIG, MUP, RIF, LEV
79 Pus swab t13150a II [2A] ERY, CLI, LEV, MOX, TOB TET, SXT, VAN, MUP, RIF, TIG, TEI, LNZ
40 Urine t648 IV [2B] – ERY, CLI, TET, SXT, VAN, MUP, MOX, RIF, TIG, TOB, TEI, LNZ, 
LEV
25 Blood t852 IV [2B] CLI#, ERY LNZ, MUP, MOX, RIF, SXT, TET, TEI, TIG, TOB, VAN LEV
35 Pus swab t345 V [5C] RIF, SXT, TET, TOB CLI, ERY, LNZ, MUP, MOX, TEI, TIG, VAN LEV
13 Pus swab t037 III [3A] CLI, ERY, SXT, TOB LNZ, MUP, MOX, RIF, TET, TEI, TIG, VAN LEV
11 Pus swab t037 III [3A] CLI#, SXT, TET, TOB ERY, LNZ, MUP, MOX, RIF, TEI, TIG, VAN LEV
89 Pus swab t13149a IV [2B] TOB, SXT, ERY CLI, LNZ, TEI, VAN, TET, TIG, MUP, RIF, LEV, MOX
75 Blood t9622 IV [2B] – ERY, CLI, TET, SXT, VAN, MUP, MOX, RIF, TIG, TOB, TEI, LNZ LEV
83 Sputum t005 IV [2B] TOB, ERY, CLI# MOX, LNZ, TEI, VAN, TET, TIG, MUP, RIF, SXT LEV
28 Nasal swab t005 IV [2B] ERY, CLI#, TOB, LEV TET, SXT, VAN, LNZ, TEI, MUP, MOX, RIF, TIG
81 Ear swab t1476 V [5C] ERY, CLI#, TET, SXT, LEV VAN, MUP, MOX, RIF, TIG, TEI, LNZ TOB
6 Nasal swab t091 V [5C] SXT, TET, TOB CLI, ERY, LNZ, MUP, MOX, RIF, TEI, TIG, VAN LEV
29 Pus swab t2029 IV [2B] CLI, ERY, RIF, SXT, TET, TOB LNZ, MUP, MOX, TEI, TIG, VAN LEV
1 Blood t037 III [3A] ERY, CLI#, TET, SXT, RIF, TOB, 
LEV
VAN, MUP, MOX, TIG, TEI, LNZ
Page 8 of 9Omuse et al. Ann Clin Microbiol Antimicrob  (2016) 15:51 
tetracycline and sulphonamide group of antibiotics 
which is fairly common amongst MRSA especially those 
that are healthcare associated. However two of the iso-
lates showed resistance to only beta lactam antibiotics 
suggesting that they may be community acquired (based 
on their molecular structure) given that they belonged 
to SCCmec type IV which has been associated with 
CA-MRSA.
The major limitation of this study is that the isolates 
characterized were not collected in a structured and con-
sistent manner and as such the proportions reported do 
not necessarily represent a true picture of the relative dis-
tributions of different clones in Nairobi due to a selection 
bias. The over representation of nasal swab specimens 
from a paediatric population from one hospital may have 
exaggerated the prevalence of t037-ST 241. We also did 
not carry out MLST and spa typing on all isolates due to 
financial constraints. However, we did ensure that a rep-
resentative isolate from each PFGE clonal complex was 
included in the isolates that were further characterized 
using MLST and spa typing.
Conclusion
To the best of our knowledge, this is the largest study 
from Kenya that has carried out PFGE, MLST, spa and 
SCCmec typing on a diverse collection of MRSA iso-
lates. This study highlights the marked genetic diver-
sity of MSSA and MRSA isolates in Nairobi including 
the presence of well-known epidemic MRSA clones and 
new MRSA spa types. Given the evolution of S. aureus 
over the years, there is need for continuous surveillance 
in order to keep track of emerging clones. The existence 
of epidemic MRSA clones further justifies the need to 
strengthen infection control measures within our hospi-
tals so as to avoid nosocomial S. aureus infections.
Abbreviations
AKUHN: Aga Khan University Hospital Nairobi; BURP: based upon repeat 
pattern; CC: clonal complex; CLSI: Clinical Laboratory Standards Institute; 
DNA: deoxyribonucleic acid; dNTP: deoxynucleotide triphosphate; EDTA: 
ethylene-diamine-tetraacetic acid; KEMRI: Kenya Medical Research Institute; 
MDR: multidrug resistance; MLST: multi-locus sequence Type; MSSA: methicil-
lin susceptible Staphylococcus aureus; MRSA: methicillin resistant Staphylococ-
cus aureus; ND: not defined; NF: no founder; PBP2a: penicillin binding protein 
2a; PCR: polymerase chain reaction; S. aureus: Staphylococcus aureus; SCCmec: 
Staphylococcal cassette chromosome mec; ST: sequence type; UT: untypeable.
Authors’ contributions
GO conceptualized the study, collected isolates, carried out molecular analysis 
and drafted the manuscript. KNVZ and KH assisted in molecular analysis of 
samples and drafting of the manuscript. SA helped in carrying out BURP 
and eBURST analysis, drafting and critiquing the manuscript. SK, AW and GV 
assisted in designing the study, getting samples, interpreting of results and 
drafting the manuscript. All authors read and approved the final manuscript.
Author details
1 Department of Pathology, Aga Khan University Hospital Nairobi, P.O. 
Box 30270-00100, Nairobi, Kenya. 2 Division of Medical Microbiology, 
Department of Pathology, Stellenbosch University, P. O. Box 19063, Western 
Cape, South Africa. 3 Division of Medical Microbiology, Department of Pathol-
ogy, Faculty of Health Sciences, University of Cape Town, South Africa, P.O. 
Box 7925, Cape Town, South Africa. 4 Center of Microbiology Research, Kenya 
Medical Research Institute, P.O. Box 54840-00200, Nairobi, Kenya. 
Acknowledgements
We acknowledge the use of the S. aureus MLST database which is located at 
Imperial College London and is funded by the Wellcome Trust.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets analysed during the current study are available from the cor-
responding author on reasonable request.
Ethics approval and consent to participate
This being a low risk study, a waiver from full ethics review was granted by the 
AKUHN research ethics committee (2016/REC-33).
Funding
All the molecular work was done in the Microbiology section, Department of 
Pathology, Tygerberg Hospital, Cape Town, South Africa. This was facilitated 
through a technology transfer grant awarded to Prof Andrew Whitelaw by 
Stellenbosch University.
Received: 10 August 2016   Accepted: 13 September 2016
References
 1. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach 
M. Survey of infections due to Staphylococcus species: frequency of 
occurrence and antimicrobial susceptibility of isolates collected in 
the United States, Canada, Latin America, Europe, and the Western 
Pacific region for the SENTRY Antimicrobial Surveillanc. Clin Infect Dis. 
2001;32(Suppl 2):S114–32.
 2. Chambers HF. The changing epidemiology of Staphylococcus aureus? 
Emerg Infect Dis. 2001;7:178–82.
 3. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and 
resurgence of meticillin-resistant Staphylococcus aureus as a public-health 
threat. Lancet. 2006;368:874–85.
 4. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King 
MD, Ray SM, Blumberg HM. Emergence of community-associated 
methicillin-resistant Staphylococcus aureus USA300 genotype as a major 
cause of health care-associated blood stream infections. Clin Infect Dis. 
2006;42:647–56.
 5. Chambers HF. Methicillin resistance in staphylococci: molecular 
and biochemical basis and clinical implications. Clin Microbiol Rev. 
1997;10:781–91.
 6. Abdulgader SM, Shittu AO, Nicol MP, Kaba M. Molecular epidemiology of 
methicillin-resistant Staphylococcus aureus in Africa: a systematic review. 
Front Microbiol. 2015;6:348.
 7. Omuse G, Kabera B, Revathi G. Low prevalence of methicillin resistant 
Staphylococcus aureus as determined by an automated identification 
system in two private hospitals in Nairobi, Kenya: a cross sectional study. 
BMC Infect Dis. 2014;14:669.
 8. Maina EK, Kiiyukia C, Wamae CN, Waiyaki PG, Kariuki S. Characterization 
of methicillin-resistant Staphylococcus aureus from skin and soft tissue 
infections in patients in Nairobi, Kenya. Int J Infect Dis. 2012;17:e115–9.
 9. Zinn CS, Westh H, Rosdahl VT. An international multicenter study of 
antimicrobial resistance and typing of hospital Staphylococcus aureus 
isolates from 21 laboratories in 19 countries or states. Microb Drug Resist. 
2004;10:160–8.
 10. Cookson BD. Methicillin-resistant Staphylococcus aureus in the com-
munity: new battlefronts, or are the battles lost? Infect Control Hosp 
Epidemiol. 2000;21:398–403.
Page 9 of 9Omuse et al. Ann Clin Microbiol Antimicrob  (2016) 15:51 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 11. Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP. MRSA in 
Africa: filling the global map of antimicrobial resistance. PLoS ONE. 
2013;8:e68024.
 12. Chatterjee SS, Otto M. Improved understanding of factors driving methi-
cillin-resistant Staphylococcus aureus epidemic waves. Clin Epidemiol. 
2013;5:205–17.
 13. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, 
Mackenzie FM. Meticillin-resistant Staphylococcus aureus (MRSA): global 
epidemiology and harmonisation of typing methods. Int J Antimicrob 
Agents. 2012;39:273–82.
 14. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The 
evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). 
Proc Natl Acad Sci USA. 2002;99:7687–92.
 15. Bozdoğan B, Yıldız O, Oryaşın E, Kırdar S, Gülcü B, Aktepe O, Arslan U, 
Bayramoğlu G, Coban AY, Coşkuner SA, Güdücüoğlu H, Karabiber N, Oncü 
S, Tatman Otkun M, Ozkütük N, Ozyurt M, Sener AG. t030 is the most 
common spa type among methicillin-resistant Staphylococcus aureus 
strains isolated from Turkish hospitals. Mikrobiyol Bul. 2013;47:571–81.
 16. David MZ, Taylor A, Lynfield R, Boxrud DJ, Short G, Zychowski D, Boyle-
Vavra S, Daum RS. Comparing pulsed-field gel electrophoresis with mul-
tilocus sequence typing, spa typing, Staphylococcal Cassette Chromo-
some mec (SCC mec) typing, and PCR for Panton–Valentine Leukocidin, 
arcA, and opp3 in methicillin-resistant Staphylococcus aureus Isola. J Clin 
Microbiol. 2013;51:814–9.
 17. Aiken AM, Mutuku IM, Sabat AJ, Akkerboom V, Mwangi J, Scott JAG, Mor-
peth SC, Friedrich AW, Grundmann H. Carriage of Staphylococcus aureus 
in Thika level 5 Hospital, Kenya: a cross-sectional study. Antimicrob Resist 
Infect Control. 2014;3:22.
 18. Robinson DA, Enright MC. Evolution of Staphylococcus aureus by large 
chromosomal replacements. J Bacteriol. 2004;186:1060–4.
 19. de Aires de Sousa M, Sanches IS, Ferro ML, Vaz MJ, Saraiva Z, Tendeiro T, 
Serra J, de Lencastre H. Intercontinental spread of a multidrug-resistant 
methicillin-resistant Staphylococcus aureus clone. J Clin Microbiol. 
1998;36:2590–6.
 20. Xu BL, Zhang G, Ye HF, Feil EJ, Chen GR, Zhou XM, Zhan XM, Chen SM, Pan 
WB. Predominance of the Hungarian clone (ST 239-III) among hospital-
acquired meticillin-resistant Staphylococcus aureus isolates recovered 
throughout mainland China. J Hosp Infect. 2009;71:245–55.
 21. Edgeworth JD, Yadegarfar G, Pathak S, Batra R, Cockfield JD, Wyncoll D, 
Beale R, Lindsay JA. An outbreak in an intensive care unit of a strain of 
methicillin-resistant Staphylococcus aureus sequence type 239 associated 
with an increased rate of vascular access device-related bacteremia. Clin 
Infect Dis. 2007;44:493–501.
 22. Wayne P. Performance standards for antimicrobial susceptibility testing; 
twentieth informational supplement. M100-S20. Clin Lab Stand Inst. 
2010:29.
 23. CDC. Oxacillin—resistant Staphylococcus aureus on PulseNet (OPN): 
Laboratory Protocol for Molecular Typing of S. aureus by Pulsed—field 
gel electrophoresis (pfge) growing cultures : plug preparation . Natl Mol 
Subtyping Netw foodborne Dis Surveill. 2013:1–24.
 24. Milheirico C, Oliveira DC, de Lencastre H. Update to the multiplex PCR 
strategy for assignment of mec element types in Staphylococcus aureus. 
Antimicrob Agents Chemother. 2007;51:4537.
 25. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus 
sequence typing for characterization of methicillin-resistant and 
methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol. 
2000;38:1008–15.
 26. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. 
Infect Genet Evol. 2008;8:747–63.
 27. Breurec S, Fall C, Pouillot R, Boisier P, Brisse S, Diene-Sarr F, Djibo S, Etienne 
J, Fonkoua MC, Perrier-Gros-Claude JD, Ramarokoto CE, Randrianirina F, 
Thiberge JM, Zriouil SB, Garin B, Laurent F. Epidemiology of methicillin-
susceptible Staphylococcus aureus lineages in five major African towns: 
high prevalence of Panton–Valentine leukocidin genes. Clin Microbiol 
Infect. 2011;17:633–9.
 28. Raji A, Ojemhen O, Umejiburu U, Ogunleye A, Blanc DS, Basset P. High 
genetic diversity of Staphylococcus aureus in a tertiary care hospital in 
Southwest Nigeria. Diagn Microbiol Infect Dis. 2013;77:367–9.
 29. Pinto AN, Seth R, Zhou F, Tallon J, Dempsey K, Tracy M, Gilbert GL, 
O’Sullivan MVN. Emergence and control of an outbreak of infections 
due to Panton–Valentine leukocidin positive, ST22 methicillin-resistant 
Staphylococcus aureus in a neonatal intensive care unit. Clin Microbiol 
Infect. 2013;19:620–7.
 30. Al-Rawahi GN, Reynolds S, Porter SD, Forrester L, Kishi L, Chong T, Bowie 
WR, Doyle PW. Community-associated CMRSA-10 (USA-300) is the 
predominant strain among methicillin-resistant Staphylococcus aureus 
strains causing skin and soft tissue infections in patients presenting to 
the emergency department of a Canadian tertiary care hospital. J Emerg 
Med. 2010;38:6–11.
 31. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient charac-
teristics of skin and soft-tissue infections in a U.S. population: a retrospec-
tive population-based study. BMC Infect Dis. 2013;13:252.
 32. Shittu A, Nübel U, Udo E, Lin J, Gaogakwe S. Characterization of meticillin-
resistant Staphylococcus aureus isolates from hospitals in KwaZulu-
Natal province, Republic of South Africa. J Med Microbiol. 2009;58(Pt 
9):1219–26.
 33. Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, Konig B, 
Konig W. Emergence of a community-associated methicillin-resistant 
Staphylococcus aureus strain with a unique resistance profile in Southwest 
Nigeria. J Clin Microbiol. 2009;47:2975–80.
 34. Stegger M, Wirth T, Andersen PS, Skov RL, De Grassi A, Simões PM, Tristan 
A, Petersen A, Aziz M, Kiil K, Cirković I, Udo EE, del Campo R, Vuopio-
Varkila J, Ahmad N, Tokajian S, Peters G, Schaumburg F, Olsson-Liljequist 
B, Givskov M, Driebe EE, Vigh HE, Shittu A, Ramdani-Bougessa N, Rasigade 
J-P, Price LB, Vandenesch F, Larsen AR, Laurent F. Origin and evolution 
of European community-acquired methicillin-resistant Staphylococcus 
aureus. MBio. 2014;5:e01044.
 35. Monecke S, Coombs G, Shore AC, Coleman DC, Akpaka P, Borg M, Chow 
H, Ip M, Jatzwauk L, Jonas D, Kadlec K, Kearns A, Laurent F, O’Brien FG, 
Pearson J, Ruppelt A, Schwarz S, Scicluna E, Slickers P, Tan HL, Weber S, 
Ehricht R. A field guide to pandemic, epidemic and sporadic clones of 
methicillin-resistant Staphylococcus aureus. PLoS One. 2011;6:e17936.
 36. Egyir B, Guardabassi L, Sørum M, Nielsen SS, Kolekang A, Frimpong E, 
Addo KK, Newman MJ, Larsen AR. Molecular Epidemiology and antimi-
crobial susceptibility of clinical Staphylococcus aureus from Healthcare 
Institutions in Ghana. PLoS ONE. 2014;9:e89716.
 37. Marais E, Aithma N, Perovic O, Oosthuysen WF, Musenge E, Dusé AG. 
Antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus 
isolates from South Africa. S Afr Med J. 2009;99:170–3.
